^
    1d
    HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion (clinicaltrials.gov)
    P=N/A, N=150, Active, not recruiting, Peking University | Not yet recruiting --> Active, not recruiting | Trial completion date: Aug 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date • Real-world evidence
    |
    Lenvima (lenvatinib) • oxaliplatin
    1d
    Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition. (PubMed, Pak J Pharm Sci)
    This combination shows promising effects and good safety in patients with HCC who have received liver transplants. Such a method offers a fresh choice for treating those who are thought not to be suitable for immunotherapy, so it needs to be tested in more extensive controlled research.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    Tecentriq (atezolizumab) • sorafenib • Lenvima (lenvatinib)
    1d
    Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, West China Hospital
    New P2 trial
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)
    1d
    QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Sun Yat-sen University
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)
    1d
    Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, West China Hospital
    New P1/2 trial
    |
    Lenvima (lenvatinib) • Enweida (envafolimab)
    2d
    CaboLu: Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=33, Suspended, University of Utah | Trial completion date: May 2028 --> Dec 2028 | Recruiting --> Suspended | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    FOLH1 positive
    |
    Cabometyx (cabozantinib tablet) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    2d
    Hederagenin Promotes Sorafenib Sensitivity in Hepatocellular Carcinoma Through Suppressing SLC7A11 Expression and Inducing Ferroptosis. (PubMed, Food Sci Nutr)
    In summary, our results demonstrated that HED synergistically promoted the anti-cancer effects of SOR on HCC cells by suppressing SLC7A11 expression, thereby triggering ferroptosis. These results suggest that HED represents a promising strategy to overcome SOR resistance and offers a viable therapeutic approach to improve SOR efficacy in patients with resistant HCC.
    Journal
    |
    SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    sorafenib
    2d
    ACSL4-driven ferroptosis susceptibility as a targetable vulnerability in monocytic acute myeloid leukemia. (PubMed, Front Oncol)
    ACSL4-high blasts showed enhanced dasatinib sensitivity (r = -0.25, P = 4.3 x 10-8). Conversely, ACSL4-high blasts showed significant ex vivo resistance to venetoclax (r = 0.36, P = 2.5 x 10-12), linking the ferroptosis-primed monocytic state to BCL2 inhibitor failure. These findings nominate ACSL4-driven ferroptosis susceptibility as a lineage-specific vulnerability rendering monocytic AML selectively sensitive to SRC-directed therapy while resistant to BCL2 inhibition.
    Journal • IO biomarker
    |
    HMOX1 (Heme Oxygenase 1) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • LPCAT3 (Lysophosphatidylcholine Acyltransferase 3)
    |
    Venclexta (venetoclax) • dasatinib
    2d
    Integrated Stress Response and Necroptosis Drive Epithelial Dysfunction in Crohn's Disease: Repurposing Cancer Drugs for Permeability Barrier Healing. (PubMed, Gastro Hep Adv)
    ISR activation and RIPK3-mediated necroptosis converge to drive epithelial injury and barrier dysfunction in CD. Repurposing pazopanib and ponatinib offers a potentially translatable approach to restore barrier integrity in CD.
    Journal
    |
    GSN (Gelsolin)
    |
    Iclusig (ponatinib) • pazopanib
    2d
    A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma. (PubMed, IJU Case Rep)
    Lenvatinib was interrupted, and intravenous piperacillin/tazobactam was administered; her symptoms improved without drainage. Lenvatinib was resumed at 8 mg with pembrolizumab, and no recurrence occurred. Early recognition and temporary interruption of lenvatinib with antibiotics may allow cautious rechallenge.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    2d
    Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma. (PubMed, JCO Precis Oncol)
    Resistance to RET inhibitors can be acquired through RET copy-number gain and secondary mutations as well as NF1 loss-mediated MAPK pathway activation. This mechanism of resistance can be overcome with dual inhibition of RET and downstream RAS/MAPK signaling, demonstrating clinical potential in RET-mutant MTC.
    Journal
    |
    RET (Ret Proto-Oncogene) • NF1 (Neurofibromin 1)
    |
    RET mutation
    |
    Mekinist (trametinib) • Retevmo (selpercatinib) • Caprelsa (vandetanib)
    3d
    ALL2620: The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in patients: MRD positive (persistent or relapsed), patients after haematological and extra-haematologicalnrelapse and patients who do not have never achieved remission after any previous treatment. (2024-516868-28-00)
    P1/2, N=67, Completed, Fondazione Gimema Franco Mandelli Onlus | Active, not recruiting --> Completed
    Trial completion • Minimal residual disease
    |
    cytarabine • Iclusig (ponatinib) • vincristine • prednisone